Unbound MEDLINE

Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Current drug metabolism [Curr Drug Metab] Journal article

 
TitleGrapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.
Author(s)Gertz M, Davis JD, Harrison A, Houston JB, Galetin A 
InstitutionSchool of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, M13 9PT, UK.
SourceCurr Drug Metab 2008 Oct; 9(8):785-95.
MeSHAnimals
Beverages
Biological Availability
Citrus paradisi
Food-Drug Interactions
Humans
Intestines
AbstractThis study aims to assess utility and limitations of grapefruit juice (GFJ) interaction studies as alternative in vivo approach to estimate intestinal availability (F(G)) in comparison to the predominantly used i.v./oral method. The F(G) estimates were obtained from the ratio of AUC in the control and the GFJ group reported previously. Due to large variability in the study design, the following inclusion criteria were applied for the selection of clinical studies: no change in elimination half-life in the presence of GFJ, administration of GFJ with or up to 4 h before drug intake, and a reported significant increase in AUC in the presence of GFJ. Weighted mean F(G) values were compared to estimates from i.v./oral data. Additionally, inter-study and inter-individual variation of GFJ F(G) estimates was assessed by meta-analysis for drugs with multiple studies reported. F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively. Overall, the inter-individual variation in GFJ F(G) estimates (16-54%) was higher than the inter-study (5.7-39%) with the exception of nisoldipine and simvastatin where inter-study variations of 53-88% were observed. Weighted average GFJ F(G) estimates were comparable to i.v./oral, supporting the application of this approach as an alternative to i.v./oral data for predominantly metabolised drugs (r(2) = 0.65; n=10). In contrast, this approach is of limited use for drugs whose disposition is co-dependent on efflux/uptake transporters and metabolic enzymes. An area of high intestinal extraction (F(G) < or = 0.25) is identified as problematic, as availability of conclusive data is limited in this area.
Languageeng
Pub Type(s)Journal Article
Research Support, Non-U.S. Gov't
Review
PubMed ID18855612
  
Advertise on this site.